Perrigo (PRGO) Non-Current Deferred Tax Liability (2013 - 2026)
Perrigo's (PRGO) quarterly Non-Current Deferred Tax Liability came in at $153.5 million in Q1 2026, down 18.87% year-on-year from $189.2 million in Q1 2025, and down 9.12% on a QoQ basis from $168.9 million in Q4 2025.
Perrigo (PRGO) Non-Current Deferred Tax Liability (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Non-Current Deferred Tax Liability data on file, last reported at $153.5 million in Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 18.87% year-over-year to $153.5 million in Q1 2026; TTM through Mar 2026 was $153.5 million, a 18.87% decrease from a year earlier, with the FY2025 full-year figure at $168.9 million, down 16.88% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $153.5 million, down from $168.9 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for PRGO reached as high as $409.1 million in Q4 2022 and fell as low as $153.5 million in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $264.0 million across 5 years, with a median of $238.9 million in 2022.
- Across the five-year window, Non-Current Deferred Tax Liability surged 68.35% in 2022 and tumbled 38.81% in 2024, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $368.2 million in 2022, then declined by 28.76% to $262.3 million in 2023, then decreased by 22.53% to $203.2 million in 2024, then dropped by 16.88% to $168.9 million in 2025, then decreased by 9.12% to $153.5 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $153.5 million in Q1 2026, $168.9 million in Q4 2025, and $194.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 153.50 Mn |
| Mar 28, 2026 | 153.50 Mn |
| Dec 31, 2025 | 168.90 Mn |
| Dec 31, 2025 | 168.90 Mn |
| Sep 27, 2025 | 194.40 Mn |
| Sep 27, 2025 | 194.40 Mn |
| Jun 28, 2025 | 206.80 Mn |
| Jun 28, 2025 | 206.80 Mn |
| Mar 29, 2025 | 189.20 Mn |
| Mar 29, 2025 | 189.20 Mn |
| Dec 31, 2024 | 203.20 Mn |
| Dec 31, 2024 | 203.20 Mn |
| Sep 28, 2024 | 213.80 Mn |
| Sep 28, 2024 | 213.80 Mn |
| Jun 29, 2024 | 211.70 Mn |
| Jun 29, 2024 | 211.70 Mn |
| Mar 30, 2024 | 247.70 Mn |
| Mar 30, 2024 | 247.70 Mn |
| Dec 31, 2023 | 262.30 Mn |
| Dec 31, 2023 | 262.30 Mn |